tiprankstipranks
Trending News
More News >
Phreesia (PHR)
NYSE:PHR

Phreesia (PHR) AI Stock Analysis

Compare
281 Followers

Top Page

PH

Phreesia

(NYSE:PHR)

Rating:71Outperform
Price Target:
$31.00
▲(8.81%Upside)
Phreesia's overall stock score is driven by strong technical momentum and positive earnings call highlights, reflecting robust revenue growth and improved cash flow. However, the negative valuation due to ongoing net losses and potential risks from legislative changes weigh on the score. Achieving profitability remains a critical challenge for future performance.
Positive Factors
Earnings
The company reported a strong start to fiscal 2026, with largely in-line sales and continued strong operating leverage, which drove a 5% raise to full-year adjusted EBITDA guidance.
Operational Performance
Phreesia's model is proving its power to drive respectable growth and strong profitability.
Negative Factors
Regulatory Risks
There is potential risk to Phreesia’s life sciences product offerings in the event of regulatory changes to direct-to-consumer pharma marketing.
Revenue Estimates
Network Solutions revenue growth normalized to 15.5% and segment revenue fell 5.0% below analyst estimates.
Revenue Growth
There is a slowdown in network solutions revenue growth, with a decrease to 16% in the quarter compared to 26% in fiscal 2025.

Phreesia (PHR) vs. SPDR S&P 500 ETF (SPY)

Phreesia Business Overview & Revenue Model

Company DescriptionPhreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
How the Company Makes MoneyPhreesia generates revenue primarily through a subscription-based model, where healthcare providers pay for access to its platform and services. The company offers various pricing tiers and modules, allowing clients to customize their usage according to their needs. In addition to subscription fees, Phreesia earns money through transaction fees from payment processing services integrated within its platform. The company may also benefit from partnerships with healthcare institutions and technology providers, which can enhance its platform offerings and expand its customer base.

Phreesia Earnings Call Summary

Earnings Call Date:May 28, 2025
(Q1-2026)
|
% Change Since: 14.19%|
Next Earnings Date:Sep 03, 2025
Earnings Call Sentiment Positive
Phreesia's earnings call shows a positive overall performance with strong revenue growth, improved EBITDA, and positive cash flows. However, there are some uncertainties regarding network solutions pacing and potential risks from legislative changes affecting pharmaceutical advertising revenue.
Q1-2026 Updates
Positive Updates
Strong Revenue Growth
Revenue was $115.9 million, an increase of 15% year-over-year.
Increased EBITDA
Adjusted EBITDA was $20.8 million, an increase of 16.7% year-over-year with an adjusted EBITDA margin of 18%.
Positive Cash Flow
Operating cash flow remained positive at $14.9 million, up $15.6 million year-over-year. Free cash flow also stayed positive at $7.5 million, up $13.7 million year-over-year.
Updated EBITDA Outlook
The company updated its adjusted EBITDA outlook for fiscal year 2026 to a range of $85 million to $90 million, an increase of $4.5 million from the prior guidance midpoint.
Growth in Healthcare Services Clients
The company ended the quarter with average healthcare services clients of 4,411, an increase of 70 from the prior quarter and 346 from the prior year.
Negative Updates
Challenges in Network Solutions Pacing
There are fluctuations in network solutions due to pacing of certain programs, which can cause variations in revenue from month-to-month or quarter-to-quarter.
Risk from Proposed Legislation
Potential impact from proposed legislation like the 'No Handouts for Drug Advertisements Act' could affect pharmaceutical advertising revenue.
Fluctuating Payment Processing Revenue
Payment processing revenue experienced a seasonal bump due to deductible resets, but future cadence remains uncertain due to typical seasonal variations.
Company Guidance
During the Phreesia First Quarter Fiscal 2026 Earnings Call, CFO Balaji Gandhi provided detailed guidance and financial performance metrics. The company reported a revenue of $115.9 million, marking a 15% year-over-year increase, and an adjusted EBITDA of $20.8 million, representing a 16.7% growth with an 18% EBITDA margin. The average healthcare services clients reached 4,411, increasing by 70 from the prior quarter and 346 from the previous year, while revenue per average healthcare services clients grew by 6% year-over-year to $26,283. The company ended the quarter with $90.9 million in cash and cash equivalents, with a positive free cash flow of $7.5 million, up $13.7 million year-over-year. Phreesia maintained its revenue outlook for fiscal year 2026 between $472 million to $482 million and revised its adjusted EBITDA range to $85 million to $90 million, reflecting a $4.5 million increase at the midpoint from previous guidance.

Phreesia Financial Statement Overview

Summary
Phreesia demonstrates strong revenue growth and operational efficiency, as reflected in the income statement. However, profitability remains a challenge with continued net losses. The balance sheet is solid with low leverage, but the negative return on equity highlights profitability issues. Cash flow metrics are improving, indicating a positive cash generation trend. Overall, while Phreesia is growing and managing its cash well, achieving profitability remains a key challenge.
Income Statement
72
Positive
Phreesia has shown consistent revenue growth over the years, with a TTM revenue of $434.5 million, up from $280.9 million in 2023. The gross profit margin remains robust at 66.3% TTM, indicating strong operational efficiency. However, the company is still facing challenges with profitability, as evidenced by the negative net profit margin of -9.8% TTM. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.
Balance Sheet
65
Positive
The company's balance sheet shows a healthy equity position with a debt-to-equity ratio of 0.06 TTM, suggesting low leverage and financial risk. The equity ratio stands at 70.5% TTM, indicating a strong equity base. However, the return on equity is negative at -15.1% TTM due to the ongoing net losses, which is a concern for potential investors.
Cash Flow
78
Positive
Phreesia's cash flow statement reveals a positive trajectory, with free cash flow growing significantly, reaching $25.5 million TTM. The operating cash flow to net income ratio is favorable at -1.12 TTM, showcasing the company's ability to generate cash from operations despite net losses. The free cash flow to net income ratio is also positive, which is a promising sign of cash flow health.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue434.53M419.81M356.30M280.91M213.23M148.68M
Gross Profit288.06M284.88M232.29M171.64M131.84M96.29M
EBITDA-9.16M-25.58M-104.00M-145.48M-92.30M-7.62M
Net Income-42.72M-58.53M-136.88M-176.15M-118.16M-27.29M
Balance Sheet
Total Assets400.39M388.42M370.33M370.06M494.48M326.67M
Cash, Cash Equivalents and Short-Term Investments90.87M84.22M87.52M176.68M313.81M218.78M
Total Debt15.87M17.80M11.98M9.18M15.80M14.32M
Total Liabilities118.21M123.61M118.88M82.24M77.20M63.36M
Stockholders Equity282.19M264.81M251.45M287.82M417.28M263.31M
Cash Flow
Free Cash Flow25.48M8.29M-57.48M-116.33M-105.52M-15.69M
Operating Cash Flow47.95M32.38M-32.38M-90.12M-74.71M2.89M
Investing Cash Flow-26.04M-24.09M-39.67M-26.20M-65.23M-25.09M
Financing Cash Flow-10.50M-11.49M-17.11M-20.41M234.97M150.66M

Phreesia Technical Analysis

Technical Analysis Sentiment
Positive
Last Price28.49
Price Trends
50DMA
25.51
Positive
100DMA
26.02
Positive
200DMA
24.48
Positive
Market Momentum
MACD
0.65
Negative
RSI
64.69
Neutral
STOCH
88.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHR, the sentiment is Positive. The current price of 28.49 is above the 20-day moving average (MA) of 26.58, above the 50-day MA of 25.51, and above the 200-day MA of 24.48, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 64.69 is Neutral, neither overbought nor oversold. The STOCH value of 88.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHR.

Phreesia Risk Analysis

Phreesia disclosed 57 risk factors in its most recent earnings report. Phreesia reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Phreesia Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
PHPHR
71
Outperform
$1.70B-15.97%16.29%66.01%
59
Neutral
$1.51B-43.33%22.29%-32.89%
51
Neutral
$7.41B0.36-61.88%2.33%17.09%1.64%
45
Neutral
$1.03B-16.71%-2.50%-30760.27%
42
Neutral
$1.44B-69.30%-68.13%
BGBGM
$2.20B-3.37%
51
Neutral
$1.64B-70.58%100.03%64.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PHR
Phreesia
28.46
7.96
38.83%
NEOG
Neogen
4.78
-10.35
-68.41%
ETNB
89bio
9.82
2.22
29.21%
BGM
Qilian International Holding Group Limited
10.59
6.39
152.14%
ARQT
Arcutis Biotherapeutics
14.02
4.72
50.75%
SDGR
Schrodinger
20.12
-0.21
-1.03%

Phreesia Corporate Events

Executive/Board ChangesShareholder Meetings
Phreesia Holds Annual Stockholders’ Meeting
Neutral
Jun 25, 2025

On June 25, 2025, Phreesia, Inc. held its annual stockholders’ meeting where three proposals were voted on. The stockholders elected two directors, Gillian Munson and Mark Smith, M.D., for a three-year term. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm was ratified, and the compensation of named executive officers was approved on a non-binding, advisory basis.

The most recent analyst rating on (PHR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Phreesia stock, see the PHR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025